MX364934B - Agente para prevenir y/o tratar dolor neuropático periférico causado por fármaco contra el cáncer. - Google Patents
Agente para prevenir y/o tratar dolor neuropático periférico causado por fármaco contra el cáncer.Info
- Publication number
- MX364934B MX364934B MX2014014505A MX2014014505A MX364934B MX 364934 B MX364934 B MX 364934B MX 2014014505 A MX2014014505 A MX 2014014505A MX 2014014505 A MX2014014505 A MX 2014014505A MX 364934 B MX364934 B MX 364934B
- Authority
- MX
- Mexico
- Prior art keywords
- preventing
- neuropathic pain
- cancer drug
- agent
- peripheral neuropathic
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 229940041181 antineoplastic drug Drugs 0.000 title abstract 2
- 208000004296 neuralgia Diseases 0.000 title abstract 2
- 208000021722 neuropathic pain Diseases 0.000 title abstract 2
- 230000002093 peripheral effect Effects 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- 208000004454 Hyperalgesia Diseases 0.000 abstract 1
- 102000012607 Thrombomodulin Human genes 0.000 abstract 1
- 108010079274 Thrombomodulin Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 206010053552 allodynia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/366—Thrombomodulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/7455—Thrombomodulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012125316 | 2012-05-31 | ||
| PCT/JP2013/063743 WO2013179910A1 (ja) | 2012-05-31 | 2013-05-17 | 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014014505A MX2014014505A (es) | 2015-06-02 |
| MX364934B true MX364934B (es) | 2019-03-28 |
Family
ID=49673113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014014505A MX364934B (es) | 2012-05-31 | 2013-05-17 | Agente para prevenir y/o tratar dolor neuropático periférico causado por fármaco contra el cáncer. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10709767B2 (enExample) |
| EP (1) | EP2857037B1 (enExample) |
| JP (3) | JP6124417B2 (enExample) |
| KR (1) | KR101672114B1 (enExample) |
| CN (1) | CN104394885B (enExample) |
| AU (1) | AU2013268725B2 (enExample) |
| BR (1) | BR112014028852A2 (enExample) |
| CA (1) | CA2875069C (enExample) |
| DK (1) | DK2857037T3 (enExample) |
| ES (1) | ES2743767T3 (enExample) |
| HU (1) | HUE045997T2 (enExample) |
| IL (1) | IL235984B (enExample) |
| IN (1) | IN2014DN10075A (enExample) |
| MX (1) | MX364934B (enExample) |
| NZ (1) | NZ702242A (enExample) |
| PL (1) | PL2857037T3 (enExample) |
| PT (1) | PT2857037T (enExample) |
| RU (1) | RU2595857C2 (enExample) |
| WO (1) | WO2013179910A1 (enExample) |
| ZA (1) | ZA201408769B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ702242A (en) * | 2012-05-31 | 2016-03-31 | Asahi Kasei Pharma Corp | Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent |
| JP6325036B2 (ja) * | 2016-08-19 | 2018-05-16 | 株式会社明治 | 抗がん剤に起因する末梢神経障害を改善するための組成物 |
| MX394717B (es) * | 2017-03-31 | 2025-03-24 | Toray Industries | Agente terapeutico o profilactico para neuropatias perifericas. |
| EP3727367A4 (en) * | 2017-12-19 | 2021-10-27 | Synergia Life Sciences Pvt. Ltd | VITAMIN K2 COMPOSITIONS FOR THE TREATMENT OF DRUG-INDUCED NEUROPATHY |
| AU2019347406B9 (en) * | 2018-09-28 | 2023-11-16 | Asahi Kasei Pharma Corporation | Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent |
| US11497795B2 (en) * | 2018-09-28 | 2022-11-15 | Asahi Kasei Pharma Corporation | Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent |
| RU2707954C1 (ru) * | 2019-01-24 | 2019-12-02 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ лечения онкологической боли |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE180496T1 (de) | 1987-01-08 | 1999-06-15 | Asahi Chemical Ind | Peptid zur beschleunigung der wirkung des proteins-c mit thrombin |
| JP2738428B2 (ja) | 1987-01-08 | 1998-04-08 | 旭化成工業株式会社 | トロンビンによるプロテインｃの活性化を促進する作用を有するペプチド |
| DE3876124T2 (de) | 1987-04-01 | 1993-05-06 | Mitsubishi Gas Chemical Co | Immunoassay fuer thrombomodulin. |
| DK299087D0 (da) | 1987-06-12 | 1987-06-12 | Novo Industri As | Proteins and derivatives thereof |
| JPS6445398A (en) | 1987-08-13 | 1989-02-17 | Kowa Co | Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody |
| JPH0720997B2 (ja) | 1988-08-29 | 1995-03-08 | 興和株式会社 | 新規なトロンビン結合性物質及びその製法 |
| JPH02255699A (ja) | 1989-03-28 | 1990-10-16 | Asahi Chem Ind Co Ltd | 新規血液抗凝固物質及びその製法 |
| JP3189052B2 (ja) | 1990-06-27 | 2001-07-16 | 持田製薬株式会社 | 抗血液凝固活性を有するポリペプチド |
| JPH05213998A (ja) | 1990-08-03 | 1993-08-24 | Asahi Chem Ind Co Ltd | 新規なポリペプチド及びこれを有効成分とする 医薬組成物 |
| US5571786A (en) | 1990-08-16 | 1996-11-05 | Immuno Aktiengesellschaft | Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation |
| JPH05310787A (ja) | 1992-05-01 | 1993-11-22 | Asahi Chem Ind Co Ltd | 新規なポリペプチド |
| JPH06205692A (ja) | 1993-01-08 | 1994-07-26 | Asahi Chem Ind Co Ltd | 新規な抗ヒトトロンボモジュリンモノクロ−ナル抗体およびその抗体を用いたヒトトロンボモジュリンの高感度測定方法 |
| JP2716267B2 (ja) | 1993-02-25 | 1998-02-18 | アボツト・ラボラトリーズ | 全血試料を高速溶解するための多目的試薬系 |
| JP3007785B2 (ja) | 1993-03-16 | 2000-02-07 | 旭化成工業株式会社 | トロンボモジュリン組成物およびその変性防止方法 |
| JPH083065A (ja) | 1994-04-20 | 1996-01-09 | Asahi Chem Ind Co Ltd | 肝臓障害に対する治療剤 |
| EP0763360B1 (en) | 1994-04-20 | 2005-02-16 | Asahi Kasei Pharma Corporation | Use of thrombomodulin for treating liver injury |
| US5916874A (en) | 1994-04-20 | 1999-06-29 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for treating liver injury |
| JP2824392B2 (ja) | 1994-05-31 | 1998-11-11 | 旭化成工業株式会社 | トロンビンによるプロテインｃの活性化を促進する作用を有するペプチドを含有する培養上澄液 |
| AU5304796A (en) | 1995-03-06 | 1996-09-23 | Interneuron Pharmaceuticals, Inc. | Reduction of infarct volume using citicoline |
| US5827832A (en) | 1995-03-06 | 1998-10-27 | Interneuron Pharmaceuticals, Inc. | Method of protecting brain tissue from cerebral infarction subsequent to ischemia |
| US5872108A (en) | 1995-03-06 | 1999-02-16 | Interneuron Pharmaceuticals, Inc. | Reduction of infarct volume using citicoline |
| JP3789147B2 (ja) | 1995-04-11 | 2006-06-21 | 旭化成ファーマ株式会社 | 脊髄損傷後の神経障害に対する治療剤 |
| JPH08301783A (ja) | 1995-05-11 | 1996-11-19 | Mochida Pharmaceut Co Ltd | 吸収性骨疾患予防・治療剤 |
| EP0743066A3 (en) | 1995-05-16 | 1998-09-30 | Mitsui Pharmaceuticals, Inc. | Wound-healing agent |
| JP3931353B2 (ja) | 1995-06-30 | 2007-06-13 | 持田製薬株式会社 | 創傷治癒剤 |
| JP3745805B2 (ja) | 1995-10-24 | 2006-02-15 | 日本ケミカルリサーチ株式会社 | トロンボモジュリンの精製方法 |
| JPH101439A (ja) | 1996-06-11 | 1998-01-06 | Mochida Pharmaceut Co Ltd | 神経変性疾患治療剤 |
| JP4157644B2 (ja) | 1998-03-30 | 2008-10-01 | 旭化成ファーマ株式会社 | 高純度可溶性トロンボモジュリンの製造方法 |
| ES2242740T3 (es) | 2000-03-28 | 2005-11-16 | Eli Lilly And Company | Proteina c activada para el tratamiento de pancreatitis. |
| US20020111296A1 (en) | 2000-08-31 | 2002-08-15 | Festoff Barry W. | Thrombomodulin analogs for use in recovery of spinal cord injury |
| EP1475098B1 (en) * | 2002-01-18 | 2015-08-05 | Asahi Kasei Pharma Corporation | High-concentration preparation of soluble thrombomodulin |
| PL1664041T3 (pl) * | 2003-09-22 | 2008-12-31 | Euro Celtique Sa | Przydatne do leczenia bólu związki fenylowo-karboksyamidowe |
| US20080280774A1 (en) * | 2005-02-16 | 2008-11-13 | Wyeth | Methods and Systems for Diagnosis, Prognosis and Selection of Treatment of Leukemia |
| US8440832B2 (en) | 2007-07-13 | 2013-05-14 | Board Of Regents, The University Of Texas System | Heterocyclic modulators of cannabinoid receptors |
| US9394267B2 (en) | 2007-07-13 | 2016-07-19 | The Cleveland Clinic Foundation | Heterocyclic modulators of cannabinoid receptors |
| KR20110008166A (ko) * | 2008-02-18 | 2011-01-26 | 라보라토리오스 델 드라. 에스테브.에스.에이. | 화학요법의 결과로 발생하는 신경병적 통증의 치료를 위한 시그마 수용체 리간드에 결합하는 화합물들의 용도 |
| US20110144024A1 (en) * | 2008-07-16 | 2011-06-16 | Paion Deutschland Gmbh | Prevention and treatment of radiation injury |
| TWI438009B (zh) * | 2010-02-19 | 2014-05-21 | Teikoku Pharma Usa Inc | 紫杉烷前－乳劑調配物及其製造與使用之方法 |
| JP2011178687A (ja) * | 2010-02-26 | 2011-09-15 | Kochi Univ | 造血細胞移植に伴う疼痛の予防および／または治療剤 |
| US20110287110A1 (en) * | 2010-04-23 | 2011-11-24 | Mark Wesley Dewhirst | Combination cancer treatment |
| JP5924611B2 (ja) | 2010-06-16 | 2016-05-25 | 国立大学法人高知大学 | 造血細胞移植に伴う生着症候群の予防及び／又は治療のための医薬 |
| JP2013533286A (ja) * | 2010-07-30 | 2013-08-22 | セントルイス ユニバーシティ | 疼痛を治療する方法 |
| NZ702242A (en) * | 2012-05-31 | 2016-03-31 | Asahi Kasei Pharma Corp | Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent |
-
2013
- 2013-05-17 NZ NZ702242A patent/NZ702242A/en unknown
- 2013-05-17 PT PT13796572T patent/PT2857037T/pt unknown
- 2013-05-17 IN IN10075DEN2014 patent/IN2014DN10075A/en unknown
- 2013-05-17 KR KR1020147032155A patent/KR101672114B1/ko active Active
- 2013-05-17 AU AU2013268725A patent/AU2013268725B2/en active Active
- 2013-05-17 US US14/404,222 patent/US10709767B2/en active Active
- 2013-05-17 ES ES13796572T patent/ES2743767T3/es active Active
- 2013-05-17 EP EP13796572.9A patent/EP2857037B1/en active Active
- 2013-05-17 JP JP2014518384A patent/JP6124417B2/ja active Active
- 2013-05-17 BR BR112014028852-6A patent/BR112014028852A2/pt not_active Application Discontinuation
- 2013-05-17 HU HUE13796572A patent/HUE045997T2/hu unknown
- 2013-05-17 CA CA2875069A patent/CA2875069C/en active Active
- 2013-05-17 DK DK13796572.9T patent/DK2857037T3/da active
- 2013-05-17 MX MX2014014505A patent/MX364934B/es active IP Right Grant
- 2013-05-17 RU RU2014148171/15A patent/RU2595857C2/ru active
- 2013-05-17 PL PL13796572T patent/PL2857037T3/pl unknown
- 2013-05-17 CN CN201380028318.4A patent/CN104394885B/zh active Active
- 2013-05-17 WO PCT/JP2013/063743 patent/WO2013179910A1/ja not_active Ceased
-
2014
- 2014-11-28 ZA ZA2014/08769A patent/ZA201408769B/en unknown
- 2014-11-30 IL IL235984A patent/IL235984B/en active IP Right Grant
-
2017
- 2017-03-31 JP JP2017071200A patent/JP6279788B2/ja active Active
-
2018
- 2018-01-17 JP JP2018005582A patent/JP6427284B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201708692B (en) | Antibacterial compounds | |
| PH12017501306A1 (en) | Inhibitors of histone demethylases | |
| MX353024B (es) | Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia. | |
| PH12015500115B1 (en) | Glucagon analogues | |
| MX364934B (es) | Agente para prevenir y/o tratar dolor neuropático periférico causado por fármaco contra el cáncer. | |
| EP3165227A4 (en) | Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria | |
| MX2014011825A (es) | INHIBIDORES DE ISOXAZOL ß-LACTAMASA. | |
| MY177912A (en) | Vegf neutralizing prodrugs for the treatment of ocular conditions | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| MX2014014832A (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa. | |
| WO2015066302A3 (en) | Compositions, methods of use, and methods of treatment | |
| CL2014003429A1 (es) | Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia. | |
| WO2016030899A8 (en) | Methods of treating amyotrophic lateral scleroses | |
| MX2016006544A (es) | Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas. | |
| MX364652B (es) | Formulacion farmaceutica que comprende ciclesonida. | |
| NZ707636A (en) | Ingenol-derived compounds that can be used for treating cancer | |
| PH12016501733A1 (en) | Pharmaceutical composition for preventing or treating skin rash | |
| WO2015027121A3 (en) | Cancer treatment | |
| EP2870964A4 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF COLITIET COMPRISING S-ALLYL-L-CYSTEINE AS ACTIVE INGREDIENT AND MEDICAL PREPARATION COMPRISING THE SAME | |
| IL234874B (en) | Triazinone compound having an inhibitory activity on a t-type calcium channel, preventive agents, therapeutic agents and medicines containing it as an active component | |
| MX2013009456A (es) | Compuestos de azufre aromaticos sustituidos y metodos para su uso. | |
| WO2014053962A3 (en) | Compositions and methods for treatment of diabetes and pre-diabetes | |
| MA39009A (fr) | Compositions pharmaceutiques comprenant un agent actif | |
| UA89548U (ru) | Фармацевтическая аэрозольная композиция для лечения бактериальных вагинозов | |
| SA515360233B1 (ar) | مثبطات إنزيمات هستون ديميثيلاز |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |